Increasing mtDNA levels as therapy for mitochondrial optic neuropathies
Ruiz-Pesini, E. (Universidad de Zaragoza) ; Emperador, S. (Universidad de Zaragoza) ; López-Gallardo, E. (Universidad de Zaragoza) ; Hernández-Ainsa, C. (Universidad de Zaragoza) ; Montoya, J. (Universidad de Zaragoza)
Resumen: Leber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma (POAG) is a frequent, acquired optic neuropathy. Lowering intraocular pressure (IOP) reduces disease progression. However, current methods to decelerate this progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic approaches. The growing evidence indicates that POAG can also be a mitochondrial optic neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial (mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation (OXPHOS) capability, and mitochondrial energy production as treatments for MONs.
Idioma: Inglés
DOI: 10.1016/j.drudis.2018.01.031
Año: 2018
Publicado en: DRUG DISCOVERY TODAY 23, 3 (2018), 493-498
ISSN: 1359-6446
Factor impacto JCR: 6.88 (2018)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 12 / 266 = 0.045 (2018) - Q1 - T1
Factor impacto SCIMAGO: 2.248 - Pharmacology (Q1) - Drug Discovery (Q1)
Financiación: info:eu-repo/grantAgreement/ES/DGA/B33
Financiación: info:eu-repo/grantAgreement/ES/DGA/FEDER
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI14-00070
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI17-00021
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI17-00166
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/P114-00005
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2020-02-17-12:42:55)
Visitas y descargas
Idioma: Inglés
DOI: 10.1016/j.drudis.2018.01.031
Año: 2018
Publicado en: DRUG DISCOVERY TODAY 23, 3 (2018), 493-498
ISSN: 1359-6446
Factor impacto JCR: 6.88 (2018)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 12 / 266 = 0.045 (2018) - Q1 - T1
Factor impacto SCIMAGO: 2.248 - Pharmacology (Q1) - Drug Discovery (Q1)
Financiación: info:eu-repo/grantAgreement/ES/DGA/B33
Financiación: info:eu-repo/grantAgreement/ES/DGA/FEDER
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI14-00070
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI17-00021
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI17-00166
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/P114-00005
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2020-02-17-12:42:55)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2019-03-20, last modified 2020-02-17